<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714594</url>
  </required_header>
  <id_info>
    <org_study_id>Saxa-Dapa 1</org_study_id>
    <nct_id>NCT03714594</nct_id>
  </id_info>
  <brief_title>Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.</brief_title>
  <official_title>A Randomized Study of the Effects of Dapagliflozin+Saxagliptin in Addition to Metformin Versus Single Addition Saxagliptin or Dapagliflozin on Glucose Metabolism in Patients With DM2 Poorly Controlled With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase IV, randomized, double-blind, single center pilot study in subjects with type 2&#xD;
      diabetes poorly controlled with metformin therapy will be randomized to receive, on top of&#xD;
      metformin: saxagliptin (5 mg/day) and dapagliflozin (10 mg/day) (Group 1);saxagliptin (5&#xD;
      mg/day) and placebo (Group 2); dapagliflozin (10 mg/day) and placebo (Group 3) for 4 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dapagliflozin (Forxiga) currently is approved for the treatment of T2DM (6). Dapagliflozin&#xD;
      inhibits SGLT2, promote the excretion of 80-90 grams of glucose per day in the urine, and&#xD;
      lower the plasma glucose concentration. This class of drugs has been shown to effectively&#xD;
      reduce the HbA1c at all stages of T2DM and can be used in combination of all other&#xD;
      anti-diabetic agents including insulin.&#xD;
&#xD;
      Saxagliptin is a highly potent DPP4 inhibitor.In patients with type 2 diabetes,&#xD;
      administration of saxagliptin led to inhibition of DPP4 enzyme activity for a 24-hour&#xD;
      period.After an oral glucose load,this DPP4 inhibition resulted in a 2- to 3-fold increase in&#xD;
      circulating levels of active incretin hormones, including glucagon-like peptide-1 (GLP-1) and&#xD;
      glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations and&#xD;
      increased glucose-dependent beta-cell responsiveness, which resulted in higher insulin and&#xD;
      C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in&#xD;
      glucagon from pancreatic alpha-cells were associated with lower fasting glucose&#xD;
      concentrations and reduced glucose excursion following an oral glucose load or a&#xD;
      meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose&#xD;
      concentrations in patients with type 2 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Metabolism</measure>
    <time_frame>from first day</time_frame>
    <description>To determine the effect of the combination of dapagliflozin (a SGLT2-inhibitor) and saxagliptin (a DPP-4 inhibitor) on pancreatic hormones secretion and endogenous glucose production in Type 2 diabetic subjects through comparison of the effects of co-administration of Saxagliptin and Dapagliflozin vs. Saxagliptin or Dapagliflozin alone.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin 5 mg + dapagliflozin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Please see Arm 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.[</description>
    <arm_group_label>Dapagliflozin 10mg</arm_group_label>
    <arm_group_label>Saxagliptin 5mg</arm_group_label>
    <other_name>forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin 5mg</intervention_name>
    <description>Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus</description>
    <arm_group_label>Saxagliptin 5mg</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin 5mg + Dapagliflozin 10 mg</intervention_name>
    <description>Please see Intervention 1 and 2</description>
    <arm_group_label>Saxagliptin 5 mg + dapagliflozin 10 mg</arm_group_label>
    <other_name>No other intervention name specified</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females&#xD;
&#xD;
          2. Age = 35-70 years&#xD;
&#xD;
          3. BMI ≤ 40 Kg/m 2 and stable weight (± 3 lbs) over the preceding three months&#xD;
&#xD;
          4. Type 2 diabetes (HbA1c &amp;gt; 7 % and &amp;lt; 10 %)&#xD;
&#xD;
          5. Metformin on stable dose (at least 1500 mg/day) for at least 12 weeks before screening&#xD;
             and at study initiation.&#xD;
&#xD;
          6. Subjects who are women of childbearing potential must agree to utilize a highly&#xD;
             effective contraceptive measure throughout the course of the study.. 7.7. Subjects are&#xD;
             capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Drugs known to affect glucose metabolism (other than metformin) for more than14 days&#xD;
             during the 12 weeks before screening&#xD;
&#xD;
          2. Known Dapagliflozin and Saxagliptin Excipient Hypersensitivity&#xD;
&#xD;
          3. Type 1 Diabetes or History of Ketoacidosis&#xD;
&#xD;
          4. history of cancer of any type;&#xD;
&#xD;
          5. cerebrovascular or symptomatic peripheral vascular disease;&#xD;
&#xD;
          6. heart disease class III or IV NYHA;&#xD;
&#xD;
          7. Estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73m 2 or serum creatinine&#xD;
             &amp;gt; 1.5mg/dL in men or &amp;gt;1.4mg/dL in women&#xD;
&#xD;
          8. Liver function enzymes higher more than two times the upper limit&#xD;
&#xD;
          9. Ongoing urinary tract infection&#xD;
&#xD;
         10. drug or alcohol abuse;&#xD;
&#xD;
         11. life expectancy &amp;lt;3 yrs&#xD;
&#xD;
         12. blood pressure &amp;gt;160/100 mmHg&#xD;
&#xD;
         13. Donation of blood to a blood bank, blood transfusion, or participation in a clinical&#xD;
             study requiring withdrawal of &amp;gt; 400 mL of blood during the 8 weeks prior to the&#xD;
             enrollment visit and at least 8 weeks thereafter&#xD;
&#xD;
         14. Women of child bearing potential who are unwilling or unable to use an acceptable&#xD;
             method to avoid pregnancy for the entire study (estrogen and/or progesterone&#xD;
             treatment)&#xD;
&#xD;
         15. Women who are pregnant or breastfeeding&#xD;
&#xD;
         16. Patient with a history or current evidence of any condition, therapy, laboratory&#xD;
             abnormality, or other circumstance which, in the opinion of the investigator or&#xD;
             coordinator, might pose an unacceptable risk to the patient or interfere with trial&#xD;
             procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Del prato</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Del prato</last_name>
    <phone>+3905099503</phone>
    <phone_ext>+3905099503</phone_ext>
    <email>segreteriadiabetologia@ao-pisa.toscana.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Daniele</last_name>
    <phone>+3905099503</phone>
    <phone_ext>+3905099503</phone_ext>
    <email>segreteriadiabetologia@ao-pisa.toscana.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism, University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Del Prato, MD</last_name>
      <phone>+39 050 995103</phone>
      <email>stefano.delprato@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Daniele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Prof. Stefano Del Prato</investigator_full_name>
    <investigator_title>Clinical Resercher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

